- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04641819
Yangzheng Compound Mixture in the Treatment of Sleep Disorder in Cancer Patients
Yangzheng Compound Mixture in the Treatment of Sleep Disorder in Cancer Patients With Qi-Yin Deficiency Syndrome During Chemotherapy: a Multicenter, Randomized, Prospective, Real-world Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Sleep disturbance is one of the most common symptoms in cancer patients, the morbidity is about 60%. Drugs commonly used to treat sleep disorders include benzodiazepines, hypnotic antidepressants and melatonin receptors agonists. The short-term efficacy of these drugs has been proven in many clinical trials, but long-term medications bear the risk of adverse reactions and addiction.
Yangzheng Compound Mixture is an extract of several traditional Chinese medicines, used as a basic prescription for cancer therapy, especially for patients who received chemotherapy with Qi-Yin deficiency syndrome, which often lead to sleep disturbance, fatigue and anorexia. According to some clinical and basic studies, Yangzheng Compound Mixture also has antitumor and immunomodulatory effects.
In this study, about 10 research centers will participate. We planned to enroll 1526 cancer patients (1144 cases in the observation group and 382 cases in the control group) with Qi-Yin deficiency Syndrome and sleep disorders during the period of receiving chemotherapy or combination of chemotherapy. The dynamic random method was adopted in this study, participants will be randomly divided into the experimental group (Yangzheng Compound Mixture plus conventional treatment) and control group (conventional treatment only), all of them will be interviewed once every 3 weeks until the end of the study.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Qi Li, PhD
- Phone Number: +86-13918191899
- Email: lzwf@hotmail.com
Study Contact Backup
- Name: Yuanyuan Feng, PhD
- Phone Number: +86-13248266010
- Email: lzwf@hotmail.com
Study Locations
-
-
Chongqing
-
Chongqing, Chongqing, China
- Chongqing University Cancer Hospital
-
-
Heilongjiang
-
Ha'erbin, Heilongjiang, China
- First Affiliated Hospital, Heilongjiang University of Chinese Medicine
-
Jiamusi, Heilongjiang, China
- Jiamusi Cancer Hospital
-
-
Henan
-
Zhengzhou, Henan, China
- Henan Cancer Hospital
-
-
Hunan
-
Changsha, Hunan, China, 410005
- The Second Affiliated Hospital of Hunan University of Chinese Medicine
-
-
Shandong
-
Jinan, Shandong, China
- The Third Affiliated Hospital of Shandong First Medical University
-
-
Shanghai
-
Shanghai, Shanghai, China
- Zhongshan Hospital
-
Shanghai, Shanghai, China, 210203
- Shuguang Hospital Affiliated with Shanghai University of TCM
-
-
Shanxi
-
Xianyang, Shanxi, China
- Affiliated Hospital of Shanxi University of Chinese Medicine
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Cancer Hospital of The University of Chinese Academy of Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18;
- Histologically or cytologically confirmed as malignant tumor;
- Receiving chemotherapy or a combination of chemotherapy;
- The syndrome differentiation of traditional Chinese medicine is the Qi-yin deficiency syndrome;
- Sleep disorders were diagnosed by investigators and the Pittsburgh Sleep Quality Index (PSQI) score was ≥ 8;
- The date of diagnosis of sleep disorder is later than the date of the first diagnosis of cancer. Or patients with sleep disorders for a long time receiving regular treatment,sleep disorders aggravated after cancer diagnosis or chemotherapy;
- Pain has been controlled well [patients were being treated with analgesics regularly,numerical rating scale(NRS) score ≤ 3];
- The participant must be able to read and express themselves clearly, can communicate with investigators and cooperate in completing the questionnaire;
- Participants voluntarily join the study with good compliance, and are willing to sign a written informed consent document;
- Survival period will be longer than 6 months.
Exclusion Criteria:
- Pregnant or lactating women;
- Allergic to Yangzheng Compound Mixture;
- Previous diagnosis of sleep apnea;
- The laboratory test value of liver and renal function is more than 2.5 times the upper limit of normal value;
- Symptoms of brain metastasis due to malignant tumor has not been effectively controlled;
- Participating in other drug clinical trials which did not allow to participate in this study;
- Refused to cooperate with follow-up;
- The researchers did not consider it appropriate for the patients to participate in this study for other reasons.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Yangzheng Compound Mixture plus conventional treatment
Yangzheng Compound Mixture: 10mL, 2 doses each time, 3 times a day, three weeks for a course of treatment. Investigators recommended that the participants of experimental group should use Yangzheng Compound Mixture for 2 courses at least. Conventional treatment: Antitumor therapies: chemotherapy or combined chemotherapy. Sleep disorders: includes but is not limited to pharmacotherapy and exercise therapy. The examination, diagnosis and treatment of other concomitant diseases and tumor complications are based on clinical routine. We will collect information about all the combined medicine. |
At the end of the treatment period, the investigator can decide whether to continue the medication based on the improvement of the subjects' sleep disturbance. Medication during the follow-up period: subjects will enter the follow-up period after completing one course of Yangzheng Compound Mixture treatment or the end of the treatment period. Visits will be conducted once every 3 weeks, at least 2 times and no more than 4 times. For subjects in the experimental group, doctors can decide whether the patients should continue to receive Yangzheng Compound Mixture therapy in the follow-up period according to the improvement of sleep disorders, while for subjects in the control group, the patients can choose to start receiving Yangzheng Compound Mixture therapy in the follow-up period according to their own wishes and doctors' suggestions.
Other Names:
Including treatment of sleep disorders and tumor which shall follow the clinical guidelines.
|
Other: conventional treatment only
Antitumor therapies: chemotherapy or combined chemotherapy. Sleep disorders: includes but is not limited to pharmacotherapy and exercise therapy. The examination, diagnosis and treatment of other concomitant diseases and tumor complications are based on clinical routine. We will collect information about all the combined medicine. |
Including treatment of sleep disorders and tumor which shall follow the clinical guidelines.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best effective rate for sleep disorder treatment
Time Frame: Measurement was taken at week 6.
|
Proportion of participants with a minimum PSQI score < 8 during the treatment period.
|
Measurement was taken at week 6.
|
Effective rate for sleep disorder treatment
Time Frame: Measurement was taken at week 6.
|
Proportion of participants with PSQI score < 8 after the end of the different treatment courses.
|
Measurement was taken at week 6.
|
Improvement rate for sleep disorder treatment
Time Frame: Measurement was taken at week 6.
|
Proportion of participates whose PSQI score decreased during treatment compared with the baseline.
|
Measurement was taken at week 6.
|
Change of PSQI score compared with baseline
Time Frame: Baseline and week 6.
|
The PSQI score difference between the end of different treatment courses and baseline.
|
Baseline and week 6.
|
Score of Pittsburgh Sleep Quality Index (PSQI), Sleep duration, Sleep efficiency, Subjective sleep quality, Sleep latency.
Time Frame: Measurement was taken at week 6.
|
|
Measurement was taken at week 6.
|
Incidence and severity of AE or SAE
Time Frame: Start of treatment until 30 days after the last day of the sleep disorder treatment
|
AE: Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. SAE: A serious adverse event (experience) or reaction is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect. |
Start of treatment until 30 days after the last day of the sleep disorder treatment
|
Incidence and severity of ADR or SADR
Time Frame: Start of treatment until 30 days after the last day of the sleep disorder treatment
|
All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions.
A SADR is a serious ADR according to the above criteria of SAE.
|
Start of treatment until 30 days after the last day of the sleep disorder treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Use frequency of hypnotic agents
Time Frame: Up to 18 weeks since the start of treatment
|
Response to question 6 of the PSQI scale.
|
Up to 18 weeks since the start of treatment
|
Appetite
Time Frame: Up to 18 weeks since the start of treatment
|
Appetite was evaluated by using the Cancer Appetite and Symptom Questionnaire(CASQ).
|
Up to 18 weeks since the start of treatment
|
Fatigue
Time Frame: Up to 18 weeks since the start of treatment
|
Fatigue was evaluated by using the Brief Fatigue Inventory(BFI).
|
Up to 18 weeks since the start of treatment
|
Quality of life (QOL)
Time Frame: Up to 18 weeks since the start of treatment
|
Quality of Life (QOL) was measured by using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30).
|
Up to 18 weeks since the start of treatment
|
Traditional Chinese Medical symptoms scale
Time Frame: Up to 18 weeks since the start of treatment
|
Traditional Chinese Medical (TCM) symptoms were measured from these six aspects: weakness, shortness of breath, palpitations, deficiency-heat and vexation, dry mouth, sweat.
The minimum score is 0 and the maximum value is 18.
Higher scores of TCM scale means a worse outcome.
|
Up to 18 weeks since the start of treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of leukocyte-increasing drugs used
Time Frame: Up to 18 weeks since the start of treatment
|
Proportion of participates used leukocyte-increasing medication during the treatment period
|
Up to 18 weeks since the start of treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Qi Li, PhD, Shuguang Hospital Affiliated with Shanghai University of TCM
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ESPRESSO
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma
-
Eye & ENT Hospital of Fudan UniversityChanghai Hospital; Fudan University; RenJi Hospital; Xinhua Hospital, Shanghai... and other collaboratorsRecruitingGlottic Carcinoma | Supraglottic Carcinoma | Subglottic Carcinoma | Pyriform Sinus Carcinoma | Postcricoid Carcinoma | Posterior Pharyngeal Wall CarcinomaChina
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast CarcinomaUnited States
-
National Cancer Institute (NCI)Not yet recruitingBreast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Estrogen Receptor-Positive Breast CarcinomaUnited States
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.WithdrawnMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial CarcinomaUnited States
-
Mamta ParikhNational Cancer Institute (NCI); Karyopharm Therapeutics IncRecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Refractory Urothelial CarcinomaUnited States
-
Ohio State University Comprehensive Cancer CenterEmbr Labs, Inc.Active, not recruitingHot Flashes | Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In SituUnited States
-
Institut BergoniéCompletedIntraductal Carcinoma and Lobular Carcinoma in SituFrance
-
National Cancer Institute (NCI)Active, not recruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Multifocal Breast Carcinoma | Synchronous Bilateral Breast CarcinomaUnited States, France, Spain, Canada, Saudi Arabia, Puerto Rico, Korea, Republic of, Ireland, Colombia, Mexico
-
University of UtahNational Cancer Institute (NCI)RecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Urothelial Carcinoma, Sarcomatoid VariantUnited States
Clinical Trials on Yangzheng Compound Mixture
-
Dalin Tzu Chi General HospitalRecruitingTinnitus | Sleep DisturbancesTaiwan
-
Ma JuanCompletedNeonatal Meconium AspirationChina
-
University of Texas Southwestern Medical CenterRecruitingObesity | Heart Failure With Preserved Ejection FractionUnited States
-
Laboratorios OrdesaUnknown
-
KU LeuvenCompletedStress | Emotions | FearBelgium
-
Royal Marsden NHS Foundation TrustMerck KGaA, Darmstadt, GermanyActive, not recruitingSoft-tissue SarcomaUnited Kingdom
-
Arafat TfayliMerck KGaA, Darmstadt, Germany; Phoenix Clinical ResearchUnknownNon-Small Cell Lung Cancer StageLebanon, Jordan
-
Chinese PLA General HospitalCompletedBreast Neoplasms | Lung NeoplasmsChina
-
Mayo ClinicCompletedBidirectional Cardiovascular ShuntUnited States
-
China Medical University HospitalWithdrawnVery Low Birth Weight InfantsTaiwan